The headline on the NICE website is “Cancer drug for children recommended after becoming cost effective for NHS patients”, but an examination of the FAD suggests otherwise:
“the range of cost-effectiveness estimates presented is higher than what NICE usually considers a cost-effective use of NHS resources. But taking into account the uncaptured health-related benefits, the rarity and severity of the disease and the potential lifetime benefit for children with neuroblastoma, dinutuximab beta can be recommended for high-risk neuroblastoma.”
Thin end of wedge?
